SPOP and prostate neoplasm: Not surprisingly, several clinical studies have shown that patients with prostate tumors bearing SPOP mutations are highly sensitive and show better response to androgen signaling inhibitors therapy, nevertheless it does not translate to survival benefit [32,33].